Dihexa raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-08. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
=== Warnings and precautions === In December 2013, the FDA added warnings to the label for clobazam, that it can cause serious skin reactions, Stevens–Johnson syndrome, and toxic epidermal necrolysis, especially in the first eight weeks of treatment.
Futurist Ray Kurzweil has shown some concern that, within the century, humans may be required to merge with this technology in order to compete in the marketplace. Enhanced individuals have a better chance of being chosen for better opportunities in careers, entertainment and resources. For example, life-extending technologies can increase the average individual life span, affecting the distribution of pension throughout the society. Increasing lifespan will affect human population, further dividing limited resources such as food, energy, monetary resources and habitat. Other critics of human enhancement fear that such capabilities would change, for the worse, the dynamic relations within a family. Given the choices of superior qualities, parents make their child as opposed to merely birthing it, and the newborn becomes a product of their will rather than a gift of nature to be loved unconditionally.
Some scholars have proposed evolutionary explanations for addiction, suggesting that vulnerabilities to substance or behavioral dependence reflect by-products or dysregulated expressions of reward and learning systems that were adaptive in ancestral environments. A 2024 review characterizes most such accounts as versions of evolutionary mismatch, in which substances and activities that are evolutionarily novel in their purity, potency or availability act on reward systems shaped under very different conditions, and extends the argument from substances to behavioral addictions. Within that framework, Nesse and Berridge argued that purified drugs and direct routes of administration bypass the systems that ordinarily evaluate experience, giving a "false signal of a fitness benefit" that hijacks the brain mechanisms underlying wanting and liking. Other reviews emphasize how psychoactive substances and behavioral reinforcers act on conserved mechanisms for reward, reinforcement, and emotion, which in modern settings can be overstimulated or maladapted. These perspectives do not replace proximate neurobiological models, but aim instead to situate contemporary patterns of vulnerability within a broader evolutionary framework.
=== Bird decline === Besides the effects of direct consumption of insecticides, populations of insectivorous birds decline due to the collapse of their prey populations. Spraying of especially wheat and corn in Europe is believed to have caused an 80 per cent decline in flying insects, which in turn has reduced local bird populations by one to two thirds.
Sources: en.wikipedia.org
=== Detection in body fluids === Nandrolone use is directly detectable in hair or indirectly detectable in urine by testing for the presence of 19-norandrosterone, a metabolite. The International Olympic Committee has set a limit of 2.0 μg/L of 19-norandrosterone in urine as the upper limit, beyond which an athlete is suspected of doping. In the largest nandrolone study performed on 621 athletes at the 1998 Nagano Olympic Games, no athlete tested over 0.4 μg/L. 19-Norandrosterone was identified as a trace contaminant in commercial preparations of androstenedione, which until 2004 was available without a prescription as a dietary supplement in the U.S. A number of nandrolone cases in athletics occurred in 1999, which included high-profile athletes such as Merlene Ottey, Dieter Baumann, and Linford Christie. However, the following year the detection method for nandrolone at the time was proved to be faulty. Mark Richardson, a British Olympic relay runner who tested positive for the substance, gave a significant amount of urine samples in a controlled environment and delivered a positive test for the drug, demonstrating that false positives could occur, which led to an overhaul of his competitive ban. Heavy consumption of the essential amino acid lysine (as indicated in the treatment of cold sores) has allegedly shown false positives in some and was cited by American shotputter C. J. Hunter as the reason for his positive test, though in 2004 he admitted to a federal grand jury that he had injected nandrolone.
Clematis addisonii Britt. – Addison's leather flower Clematis akebioides (Maxim.) H.J.Veitch Clematis albicoma Wherry – whitehair leather flower Clematis alpina (L.) Mill. – alpine clematis Clematis aristata R.Br. ex Ker Gawl. – Australian clematis Clematis armandii – Armand clematis Clematis baldwinii Torr. & A.Gray – pine hyacinth Clematis bigelovii Torr. – Bigelow clematis Clematis brachiata Thunb. – traveller's joy Clematis campaniflora Brot. – Portuguese clematis Clematis catesbyana – satin curls Clematis chinensis Osbeck – wei ling xian in Chinese (Chinese: 威靈仙; pinyin: Wei ling xian) Clematis chrysocoma Franch. – gold wool clematis Clematis cirrhosa L. – includes the 'Freckles', 'Wisley Cream', and 'Jingle Bells' cultivars Clematis cirrhosa v. balearica (Balearic Islands) Clematis coactilis (Fern.) Keener – Virginia whitehair leather flower Clematis columbiana (Nutt.) Torr. & A.Gray – British Columbia virgin's bower Clematis crispa L. – swamp leather flower Clematis cunninghamii Clematis dioica L. – cabellos de angel Clematis drummondii Torr. & A.Gray – Drummond clematis Clematis durandii Clematis fawcettii F.Muell. Clematis flammula L. – fragrant virgin's bower Clematis florida Thunb. – Asian clematis Clematis foetida Raoul (1846) – New Zealand clematis Clematis fremontii S.Watson – Fremont's leather flower Clematis glaucophylla Small – whiteleaf leather flower Clematis glycinoides DC. – headache vine Clematis gouriana – Indian traveller's joy Clematis henryi Oliv. Clematis hirsutissima Pursh – hairy clematis Clematis hedysarifolia DC. Clematis integrifolia L.
In genetics, a nonsense mutation is a point mutation in a sequence of DNA that results in a nonsense codon, or a premature stop codon in the transcribed mRNA, and leads to a truncated, incomplete, and possibly nonfunctional protein product. Nonsense mutations are not always harmful; the functional effect of a nonsense mutation depends on many aspects, such as the location of the stop codon within the coding DNA. For example, the effect of a nonsense mutation depends on the proximity of the nonsense mutation to the original stop codon, and the degree to which functional subdomains of the protein are affected. As nonsense mutations lead to premature termination of polypeptide chains, they are also called chain termination mutations. Missense mutations differ from nonsense mutations since they are point mutations that exhibit a single nucleotide change to cause substitution of a different amino acid. A nonsense mutation also differs from a nonstop mutation, which is a point mutation that removes a stop codon. About 10% of patients facing genetic diseases have involvement with nonsense mutations. Some of the diseases that these mutations can cause are Duchenne muscular dystrophy (DMD), cystic fibrosis (CF), spinal muscular atrophy (SMA), cancers, metabolic diseases, and neurologic disorders. The rate of nonsense mutations is variable from gene-to-gene and tissue-to-tissue, but gene silencing occurs in every patient with a nonsense mutation.
Sources: en.wikipedia.org
=== Statistics === Southern Rhodesia had contributed more manpower to the Allied cause in World War II, proportional to white population, than any other British dominion or colony, and more than the UK itself. According to figures compiled by MacDonald for his War History of Southern Rhodesia, 26,121 Southern Rhodesians served in the armed forces during the conflict, of whom 2,758 were commissioned officers. Broken down by race and gender, there were 15,153 black men, 9,187 white men, 1,510 white women and 271 coloured and Indian men. Of the 8,390 who served outside the territory, 1,505 were black men, 6,520 were white men, 137 were white women and 228 were coloured or Indian men. According to official figures, 33,145 black Southern Rhodesians were conscripted for labour between 1943 and 1945; Vickery estimates that between 15,000 and 60,000 more may have worked on the aerodromes. According to Ashley Jackson's work The British Empire and the Second World War, the Rhodesian Air Training Group instructed 8,235 Allied pilots, navigators, gunners, ground crew and others—about 5% of overall EATS output. A total of 2,409 Southern Rhodesians (977 officers and 1,432 other ranks) served in the RAF during the war, 373 (86 officers and 287 ratings) joined the Royal Navy, and 13 officers and 36 ratings from Southern Rhodesia mustered into the South African Navy. The vast majority of the rest served in either the Southern Rhodesian territorial forces or the British or South African Army.
Fibromyalgia can be viewed as a condition defined by nociplastic pain. Nociplastic pain is caused by altered function of pain-related sensory pathways in the periphery and the central nervous system, resulting in hypersensitivity. As of 2023, the underlying processes of nociplastic pain remain poorly understood. Nociplastic pain may be caused by either (1) increased processing of pain stimuli or (2) decreased suppression of pain stimuli at several levels in the nervous system, or both. Nociplastic pain has been referred to as "Nociplastic pain syndrome" because it is coupled with other symptoms including fatigue, sleep disturbance, cognitive disturbance, hypersensitivity to environmental stimuli, anxiety, and depression. Nociplastic pain states can be triggered by a variety of stressors such as trauma, infections, and chronic stressors. A 2024 review reported that symptoms such as fatigue, sleep, memory, and mood problems, and sensitivity to non-painful sensory stimuli were also CNS-driven symptoms that were inherent to nociplastic pain. In 2023, the "Fibromyalgia: Imbalance of Threat and Soothing Systems" (FITSS) model was suggested as a working hypothesis. According to the FITSS model, the salience network (also known as the midcingulo-insular network) may remain continuously hyperactive due to an imbalance in emotional self-regulation, which is reflected by an overactive "threat" system and an underactive "soothing" system. This hyperactivation, along with other mechanisms, may contribute to fibromyalgia.
== Units == The SI unit of dynamic viscosity is the newton-second per metre squared (N·s/m2), also frequently expressed in the equivalent forms pascal-second (Pa·s), kilogram per meter per second (kg·m−1·s−1) and poiseuille (Pl). The CGS unit is the poise (P, or g·cm−1·s−1 = 0.1 Pa·s), named after Jean Léonard Marie Poiseuille. It is commonly expressed, particularly in ASTM standards, as centipoise (cP). The centipoise is convenient because the viscosity of water at 20 °C is about 1 cP, and one centipoise is equal to the SI millipascal second (mPa·s). The SI unit of kinematic viscosity is metre squared per second (m2/s), whereas the CGS unit for kinematic viscosity is the stokes (St, or cm2·s−1 = 0.0001 m2·s−1), named after Sir George Gabriel Stokes. In U.S. usage, stoke is sometimes used as the singular form. The submultiple centistokes (cSt) is often used instead, 1 cSt = 1 mm2·s−1 = 10−6 m2·s−1. 1 cSt is 1 cP divided by 1000 kg/m^3, close to the density of water. The kinematic viscosity of water at 20 °C is about 1 cSt. The most frequently used systems of US customary, or Imperial, units are the British Gravitational (BG) and English Engineering (EE). In the BG system, dynamic viscosity has units of pound-seconds per square foot (lb·s/ft2), and in the EE system it has units of pound-force-seconds per square foot (lbf·s/ft2). The pound and pound-force are equivalent; the two systems differ only in how force and mass are defined.
Westbrook* (1968), writer, son of syndicated columnist Sheilah Graham Westbrook Phillip Lopate (1964), essayist and fiction writer Ron Padgett (1964), poet and translator, winner of the Shelley Memorial Award in 2009 and Robert Frost Medal in 2018 Steven Millhauser (1965), novelist and winner of the Pulitzer Prize for Fiction for Martin Dressler: The Tale of an American Dreamer Aaron Fogel (1967), poet Eric Van Lustbader (1967), espionage and thriller novelist, writer of Jason Bourne novels Thomas Hauser (1968), author of nonfiction and biographer David Shapiro (1968), poet, literary critic, professor at William Paterson University Hilton Obenzinger (1969), novelist, poet, history and criticism writer Paul Auster (1970), postmodern writer; author of The New York Trilogy, Moon Palace, and the Brooklyn Follies Bob Holman (1970), poet and activist identified with the oral tradition David Lehman (1970), poet, editor of The Best American Poetry series Joshua Rubenstein (1971), writer, winner of a National Jewish Book Award in 2002 Alex Abella (1972), Cuban-American writer Brad Gooch (1973), writer, professor of English at William Paterson University John Prados (1973), author and historian on World War II and the Cold War Todd McEwen (1975), writer, professor at the University of Kent Stephen O'Connor (1975), writer and professor at Sarah Lawrence College Damien Bona (1977), chronicler of the Academy Awards Mason Wiley (1977), co-author of The Official Preppy Handbook Kevin Baker (1980), novelist and freelance journalist Jeffrey Harrison (1980), poet who won the 1988 Amy Lowell Poetry Travelling Scholarship Lou Antonelli (1981), science fiction writer Douglas Sadownick (1981), writer and psychologist Michael Friedman (1982), novelist and author Michael Azerrad (1983), author, journalist, musician Thomas Dyja (1984), writer, historian, winner of the 1997 Casey Award David Rakoff (1986), comedic essayist Louise Wareham Leonard (1987), writer Al Weisel (1987), freelance writer Adrienne Brodeur (1988), author, program director at Aspen Institute Glen Hirshberg (1988), author, recipient of the 2007 Shirley Jackson Award Adam Mansbach (1988), author and former professor of literature at Rutgers University–Camden Darryl Pinckney (1988), novelist, playwright, and essayist Mako Yoshikawa (1988), novelist, professor at Emerson College Ben Coes (1989), author of political thriller and espionage novels Wade Graham (1989), author, historian, environmentalist G. Winston James (1989), poet, author, activist Robert Salkowitz (1989), author on technology innovation Carol Guess (1990), novelist and poet; professor at Western Washington University John Reed (1990), novelist; author of Snowball's Chance David S. Levinson (1991), short-story writer and novelist Robert Kolker (1991), writer, author of Hidden Valley Road Kelly Link (1991), Hugo Award-winning author; founder of Small Beer Press; editor of St. Martin's Press's Year's Best Fantasy and Horror Loren Goodman (1991), postmodern poet, professor at Underwood International College Andrew Carroll (1992), author, editor, activist, and historian Jordan Davis (1992), poet John Bemelmans Marciano (1992), children's book author and illustrator, grandson of Ludwig Bemelmans, author of Madeline Marie Mutsuki Mockett (1992), writer Melissa de la Cruz (1993), writer known for work in young adult fiction Jay Michaelson (1993), writer and LGBTQ activist Maxine Swann (1994), fiction writer Robert Westfield (1994), writer who won two Lambda Literary Awards Megan McCafferty (1995), chick lit writer, Jessica Darling series, which were plagiarized by Kaavya Viswanathan Tova Mirvis (1995), author Saleemah Abdul-Ghafur (1996), author and Islamic activist Fredrik Stanton (1996), author of Great Negotiations and former publisher for the Columbia Daily Spectator Aravind Adiga (1997), Man Booker Prize-winning novelist Jamel Brinkley (1997), author, winner of the 2018 Ernest J. Gaines Award for Literary Excellence John Coletti (1997), author Gotham Chopra (1997), author, son of health advocate Deepak Chopra Lauren Grodstein (1997), author, professor of Rutgers University–Camden Abdi Nazemian (1998), Iranian-American author, winner of the 2017 Lambda Literary Award for Debut Fiction Trevor Shane (1998), writer Daniel Alarcón (1999), novelist Katherine Howe (1999), novelist, author of The Physick Book of Deliverance Dane Rebecca Pawel (1999), author of mystery novels; winner of the 2004 Edgar Allan Poe Award for Best First Novel Alex Marzano-Lesnevich (2001), author, winner of a 2018 Lambda Literary Award and Chautauqua Prize Fiona Sze-Lorrain (2003), French writer, poet, translator, musician Ben Dolnick (2004), writer, son of biographer Edward Dolnick, member of the Ochs-Sulzberger family that owns The New York Times Danielle Valore Evans (2004), fiction writer Adam Gidwitz (2004), author of best selling children's books Alaya Dawn Johnson (2004), author and winner of the 2015 Andre Norton Award Tongo Eisen-Martin (2004), poet laureate of San Francisco Sidik Fofana (2005), public school teacher and writer, winner of a 2023 Whiting Award Victoria Loustalot (2006), writer of memoir and essays Crystal Hana Kim (2009), writer, If You Leave Me Morgan Parker (2010), poet and Cave Canem Fellow Rachel Heng (2011), Singaporean writer Ben Philippe (2011), author, screenwriter, recipient of the 2020 William C. Morris Award Rowan Hisayo Buchanan (2012), British-American writer, recipient of the Betty Trask Award and the Authors' Club Best First Novel Award Sylvia Khoury (2012), writer and playwright, recipient of a 2021 Whiting Award Yanyi (2013), poet
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.